University of Hertfordshire

From the same journal

By the same authors

Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma

Research output: Contribution to journalArticlepeer-review

Standard

Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma. / Van Praet, Charles; Slots, Charlotte; Vasdev, Nikhil; Rottey, Sylvie; Fonteyne, Valérie; Andras, Iulia; Albersen, Maarten; De Meerleer, Gert; Bex, Axel; Decaestecker, Karel.

In: Turkish Journal of Urology , 25.01.2021.

Research output: Contribution to journalArticlepeer-review

Harvard

Van Praet, C, Slots, C, Vasdev, N, Rottey, S, Fonteyne, V, Andras, I, Albersen, M, De Meerleer, G, Bex, A & Decaestecker, K 2021, 'Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma', Turkish Journal of Urology .

APA

Van Praet, C., Slots, C., Vasdev, N., Rottey, S., Fonteyne, V., Andras, I., Albersen, M., De Meerleer, G., Bex, A., & Decaestecker, K. (Accepted/In press). Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma. Turkish Journal of Urology .

Vancouver

Van Praet C, Slots C, Vasdev N, Rottey S, Fonteyne V, Andras I et al. Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma. Turkish Journal of Urology . 2021 Jan 25.

Author

Van Praet, Charles ; Slots, Charlotte ; Vasdev, Nikhil ; Rottey, Sylvie ; Fonteyne, Valérie ; Andras, Iulia ; Albersen, Maarten ; De Meerleer, Gert ; Bex, Axel ; Decaestecker, Karel. / Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma. In: Turkish Journal of Urology . 2021.

Bibtex

@article{a704a32f51a541608847a2c9014e1d40,
title = "Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma",
abstract = "Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have questioned the role of immediate CN and initiated an ongoing debate on the proper indications and timing of CN. Although some patients still benefit from immediate CN, other patients require immediate systemic treatment, and some of them might benefit from deferred CN in the absence of disease progression. This study provides an overview of the history of CN, an in-depth analysis of SURTIME and CARMENA, and highlights the current indications for performing immediate or deferred CN.",
author = "{Van Praet}, Charles and Charlotte Slots and Nikhil Vasdev and Sylvie Rottey and Val{\'e}rie Fonteyne and Iulia Andras and Maarten Albersen and {De Meerleer}, Gert and Axel Bex and Karel Decaestecker",
year = "2021",
month = jan,
day = "25",
language = "English",
journal = "Turkish Journal of Urology ",
issn = "2149-3057",
publisher = "Aves",

}

RIS

TY - JOUR

T1 - Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma

AU - Van Praet, Charles

AU - Slots, Charlotte

AU - Vasdev, Nikhil

AU - Rottey, Sylvie

AU - Fonteyne, Valérie

AU - Andras, Iulia

AU - Albersen, Maarten

AU - De Meerleer, Gert

AU - Bex, Axel

AU - Decaestecker, Karel

PY - 2021/1/25

Y1 - 2021/1/25

N2 - Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have questioned the role of immediate CN and initiated an ongoing debate on the proper indications and timing of CN. Although some patients still benefit from immediate CN, other patients require immediate systemic treatment, and some of them might benefit from deferred CN in the absence of disease progression. This study provides an overview of the history of CN, an in-depth analysis of SURTIME and CARMENA, and highlights the current indications for performing immediate or deferred CN.

AB - Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have questioned the role of immediate CN and initiated an ongoing debate on the proper indications and timing of CN. Although some patients still benefit from immediate CN, other patients require immediate systemic treatment, and some of them might benefit from deferred CN in the absence of disease progression. This study provides an overview of the history of CN, an in-depth analysis of SURTIME and CARMENA, and highlights the current indications for performing immediate or deferred CN.

M3 - Article

JO - Turkish Journal of Urology

JF - Turkish Journal of Urology

SN - 2149-3057

ER -